Cardiovascular Risk Reduction After Renal Denervation According to Time in Therapeutic Systolic Blood Pressure Range

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Hypertension Management

Background:

• Renal denervation (RDN) is known to reduce blood pressure (BP), but its impact on cardiovascular events requires further investigation.
• Time in therapeutic range (TTR) for BP is a recognized predictor of cardiovascular outcomes.

Purpose of the Study:

• To evaluate the effect of catheter-based RDN on TTR.
• To assess the association between TTR and cardiovascular outcomes in patients within the Global SYMPLICITY Registry (GSR).

Main Methods:

• Radiofrequency RDN was performed on patients with uncontrolled hypertension.
• Office and ambulatory systolic BP (OSBP and ASBP) were monitored for 36 months to calculate TTR.
• Cox proportional hazard regression analyzed TTR at 6 months as a predictor of cardiovascular events from 6 to 36 months.

Main Results:

• The study enrolled 3,077 patients with sustained BP reductions at 36 months post-RDN.
• TTR through 6 months was 30.6%.
• A 10% increase in TTR was associated with significant risk reductions: 15% for MACE, 11% for CV death, 15% for MI, and 23% for stroke.

Conclusions:

• RDN leads to sustained BP reduction and improved TTR up to 36 months.
• Enhanced TTR following RDN is a significant predictor of reduced major cardiovascular events.
• The findings support RDN as a valuable therapeutic option for managing hypertension and its associated cardiovascular risks.